Nonagen Bioscience® combines urine-based liquid biopsy, multiplex proteomics, clinical data and proprietary computational algorithms to detect cancer, monitor recurrence and predict treatment response.

3 Commercial Tests | 5,500+ Patients | 40+ Publications | $21M+ NIH/NCI Funding

One Platform. Three Clinical Decisions.

DETECT — Aid in the detection of urothelial cancer
MONITOR — Monitor for bladder cancer recurrence
PREDICT — Predict response to BCG therapy

Clearly different. Clearly better.